Skip to content

Kodiak Sciences Inc KOD Additional Paid-In Capital

Additional Paid-In Capital at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$14.4B+9.2%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$1.83B+49.6%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.95B+30.0%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$942.7M+29.5%
Vera Therapeutics logo
Vera TherapeuticsVERA
$1.38B+31.9%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$4.48B+5.4%

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Reported directly by Kodiak Sciences Inc in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's additional paid-in capital?
Kodiak Sciences Inc (KOD) reported additional paid-in capital of $1.73B in Q1 2026.
How has Kodiak Sciences Inc's additional paid-in capital changed year-over-year?
Kodiak Sciences Inc's additional paid-in capital increased by 15.6% year-over-year, from $1.5B to $1.73B.
What is the long-term trend for Kodiak Sciences Inc's additional paid-in capital?
Over 5 years (2020 to 2025), Kodiak Sciences Inc's additional paid-in capital has grown at a 8.3% compound annual growth rate (CAGR), from $1.15B to $1.72B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.